Takeda Pharmaceutical Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of neonatal-onset multisystem inflammatory disease (NOMID/CINCA), Muckle-Wells syndrome, familial cold autoinflammatory syndrome, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and prion disease.